BrainStorm touts preclinical work; Antisoma encouraged by mid-stage AML trial;

> BrainStorm Cell Therapeutics says that preclinical work on its adult stem cell therapy for spinal cord injuries has demonstrated efficacy in rats. BrainStorm release 

> Antisoma says that encouraging results from a Phase II study of a new therapy for AML has convinced researchers to increase the dosage in the next mid-stage trial. Release

> Neurobiological Technologies announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. Release

> A federal judge is urging Eli Lilly to negotiate a worldwide settlement with Zyprexa plaintiffs, who are asking for some $7.7 billion. Zyprexa report

> Where's the growth? According to a Financial Times survey, a quarter of pharma execs agree that diversifying away from medications and stepping up sales in emerging markets are the way to go. Report

> Good news for makers of cholesterol meds: The market has just expanded. For the first time, the American Academy of Pediatrics is recommending that kids as young as 8 years old be given cholesterol drugs in hopes of preventing future heart disease. Report

> A German company is snapping up APP Pharmaceuticals in a deal worth more than $4.6 billion. Report

And Finally... A woman in southern Ontario is one of the first cases in Canada of a rare neurological syndrome in which a person starts speaking with a different accent, McMaster University researchers report in the July issue of the Canadian Journal of Neurological Sciences. Release